Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Mirum Pharmaceuticals (MIRM) Total Liabilities: 2020-2024

Historic Total Liabilities for Mirum Pharmaceuticals (MIRM) over the last 5 years, with Dec 2024 value amounting to $445.1 million.

  • Mirum Pharmaceuticals' Total Liabilities rose 13.12% to $493.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $493.1 million, marking a year-over-year increase of 13.12%. This contributed to the annual value of $445.1 million for FY2024, which is 11.85% up from last year.
  • According to the latest figures from FY2024, Mirum Pharmaceuticals' Total Liabilities is $445.1 million, which was up 11.85% from $398.0 million recorded in FY2023.
  • Mirum Pharmaceuticals' Total Liabilities' 5-year high stood at $445.1 million during FY2024, with a 5-year trough of $68.8 million in FY2020.
  • Moreover, its 3-year median value for Total Liabilities was $398.0 million (2023), whereas its average is $351.3 million.
  • Data for Mirum Pharmaceuticals' Total Liabilities shows a peak YoY surged of 153.66% (in 2021) over the last 5 years.
  • Mirum Pharmaceuticals' Total Liabilities (Yearly) stood at $68.8 million in 2020, then spiked by 153.66% to $174.4 million in 2021, then increased by 20.88% to $210.9 million in 2022, then surged by 88.72% to $398.0 million in 2023, then increased by 11.85% to $445.1 million in 2024.